Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer

Prostate

Volumn 73, Issue 7, 2013, Pages 763-769

  Pértega Gomes, Nelma ^a,b   Vizcaíno, José R ^c   Gouveia, Carlos ^c   Jerõnimo, Carmen ^d,e   Henrique, Rui M ^d,e   Lopes, Carlos ^c,e   Baltazar, Fátima ^a,b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c Centro Hospitalar Universitario do Porto   (Portugal)

^d PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

alpha methylacyl CoA racemase; cancer biomarkers; prostate cancer diagnosis

Indexed keywords

34BETAE12 PROTEIN; ALPHAMETHYLACYL COA RACEMASE; MONOCARBOXYLATE TRANSPORTER 2; PROTEIN; PROTEIN P63; RACEMASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; GENE OVEREXPRESSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

BIOLOGICAL MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MONOCARBOXYLIC ACID TRANSPORTERS; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; RACEMASES AND EPIMERASES; SENSITIVITY AND SPECIFICITY;

EID: 84874219218     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22620     Document Type: Article

References (23)

1. Ferlay J, Bray F, Pisani P,. Globocan 2002: Cancer incidence, mortality and prevalence worldwide. Version 2.0. Lyon, France: IARC Press; 2004. IARC CancerBase No. 5.
2. Gaudin PB, Reuter VE,. Benign mimics of prostatic adenocarcinoma on needle biopsy. Anat Pathol 1997; 2: 111-134.
3. Vander Heiden MG,. Targeting cancer metabolism: A therapeutic window opens. Nat Rev Drug Discov 2011; 10 (9): 671-684.
4. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F,. Role of monocarboxylate transporters in human cancers: State of the art. J Bioenerg Biomembr 2012; 44 (1): 127-139.
5. Pértega-Gomes N, Vizcaíno JR, Miranda-Gonçalves V, Pinheiro C, Silva J, Pereira H, Monteiro P, Henrique RM, Reis RM, Lopes C, Baltazar F,. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer 2011; 11: 312.
6. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM,. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822-826.
7. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB,. Human prostate cancer and benign prostatic hyperplasia: Molecular dissection by gene expression profiling. Cancer Res 2001; 61: 4683-4688.
8. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr, Hampton GM,. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001; 61: 5974-5978.
9. Ferdinandusse S, Denis S, IJlst L, Dacremont G, Waterham HR, Wanders RJ,. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res 2000; 41: 1890-1896.
10. Kotti TJ, Savolainen K, Helander HM, Yagi A, Novikov DK, Kalkkinen N, Conzelmann E, Hiltunen JK, Schmitz W,. In mouse alpha-methylacyl-CoA racemase, the same gene product is simultaneously located in mitochondria and peroxisomes. J Biol Chem 2000; 275: 20887-20895.
11. Yang XJ, Wu CL, Woda BA, Dresser K, Tretiakova M, Fanger GR, Jiang Z,. Expression of alphamethylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 2002; 26: 921-925.
12. Jiang Z, Li C, Fischer A, Dresser K, Woda BA,. Using an AMACR (P504S)/34βE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy. Am J Clin Pathol 2005; 123: 231-236.
13. Wojno KJ, Epstein JI,. The utility of basal cell-specific anticytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer; a review of 228 cases. Am J Surg Pathol 1995; 19: 251-260.
14. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M,. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000; 157: 1769-1775.
15. Weinstein M, Signoretti S, Loda M,. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol 2002; 15: 1302-1308.
16. Parsons J, Gage W, Nelson W, De Marzo AM,. p63 protein expression is rare in prostate adenocarcinoma: Implications for cancer diagnosis and carcinogenesis. Urology 2001; 58: 619-624.
17. Edge SB, Byrd DR, Compton CC,. AJCC cancer staging manual, 7th edition. Chicago: Springer; 2010.
18. Epstein J, Allsbrook W, Amin M, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29: 1228-1242.
19. Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, Pihan G, Cai F, Babcook JS, Rathanaswami P, Reed SG, Xu J, Fanger GR,. P504S: A new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001; 25 (11): 1397-1404.
20. Ng VW, Koh M, Tan SY, Tan PH,. Is triple immunostaining with 34βE12, p63, and racemase in prostate cancer advantageous? A tissue microarray study. Am J Clin Pathol 2007; 127 (2): 248-253.
21. DiGiuseppe JA, Sauvageot J, Epstein JI,. Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol 1997; 21: 174-178.
22. Epstein JI,. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol 1995; 26: 223-229.
23. Epstein JI, Potter SR,. The pathological interpretation and significance of prostate needle biopsy findings: Implications and current controversies. J Urol 2001; 166: 402-410.